Breaking News Instant updates and real-time market news.

ALKS

Alkermes

$47.03

0.32 (0.69%)

07:02
10/03/16
10/03
07:02
10/03/16
07:02

Alkermes announces initiation of ALKS 3831 study for schizophrenia treatment

Alkermes announced the initiation of a clinical study designed to evaluate the metabolic profile of ALKS 3831, an investigational, novel, oral atypical antipsychotic drug candidate, compared to olanzapine, an established atypical antipsychotic agent with proven efficacy but also metabolic liabilities, including significant weight gain. The randomized, double-blind, parallel-group study will characterize metabolic parameters, including insulin sensitivity and lipid metabolism, in response to treatment with ALKS 3831 and olanzapine. This exploratory metabolic study in healthy subjects is a supportive study in the ENLIGHTEN pivotal program of ALKS 3831 for the treatment of schizophrenia. The two key phase 3 studies, ENLIGHTEN-1 and ENLIGHTEN-2, have been enrolling patients since December 2015 and February 2016, respectively. The objective of the newly-initiated metabolic study is to more fully characterize the comparative metabolic effects of ALKS 3831 and olanzapine, in order to understand the potential metabolic benefits of ALKS 3831 and to build on the findings from previously conducted preclinical and clinical studies that suggest treatment with ALKS 3831 is associated with less weight gain compared to olanzapine. ALKS 3831 is designed to provide patients with the strong efficacy of olanzapine with favorable weight and metabolic properties. The phase 1 metabolic study will assess the effects of ALKS 3831 on whole body insulin sensitivity, lipid metabolism and other important metabolic parameters compared to olanzapine. Approximately 50 healthy subjects will be randomized to receive ALKS 3831, olanzapine or placebo for 21 days. Results from the study are expected in the first half of 2017.

  • 06

    Nov

ALKS Alkermes
$47.03

0.32 (0.69%)

07/29/16
FBCO
07/29/16
NO CHANGE
Target $52
FBCO
Outperform
Alkermes quarter raised some questions, says Credit Suisse
Credit Suisse analyst Vamil Divan says Alkermes' Q2 results, while solid overall, raised some questions. The stock came under pressure yesterday given some questions around net pricing for Vivitrol as well development timelines around ALKS 8700, Divan tells investors in a post-earnings research note. Vivitrol sales slightly missed what some investors were hoping for since an increased percentage of volume came at lower net prices from Medicaid customers, the analyst contends. Divan remains bullish on the overall story and views the stock's risk/reward as attractive ahead of the FORWARD-5 data by year-end. He raised his price target for the shares to $52 from $45 and keeps an Outperform rating on Alkermes.
07/29/16
COWN
07/29/16
NO CHANGE
Target $60
COWN
Outperform
Alkermes weakness a buying opportunity, says Cowen
Cowen said the weakness in Alkermes is a buying opportunity as they believe the magnitude, sustainability, and impact of Vivitrol's growth is being meaningfully underestimated by the Street. Cowen reiterated its Outperform rating and $60 price target on Alkermes shares.
09/27/16
SBSH
09/27/16
NO CHANGE
Target $53
SBSH
Neutral
Alkermes price target raised to $53 from $44 at Citi
Citi analyst Liav Abraham raised her price target for Alkermes to $53 after the company hosted an investor event to overview the various aspects of Vivitrol. Alkermes' execution on a "unique commercial model," which targets the differing opioid addiction population needs on a state-by-state basis, is likely to drive robust volume growth going forward, particularly in the Medicaid patient population, Abraham tells investors in a research note. The analyst raised her estimates for Vivitrol but remains cautious on the FORWARD-5 data for ALKS 5461 due out in Q4. As such, Abraham keeps a Neutral rating on Alkermes.
09/27/16
JEFF
09/27/16
NO CHANGE
Target $62
JEFF
Buy
Alkermes sees significant room for Vivitrol upside, says Jefferies
Alkermes yesterday at its Vivitrol-focused event highlighted that the opioid treatment is still in the early stages of growth, Jefferies analyst Biren Amin tells investors in a research note. The company estimates that Vivitrol is currently capturing only 2% average market share and believes room for upside is significant, the analyst writes. He keeps a Buy rating on Alkermes with a $62 price target.

TODAY'S FREE FLY STORIES

DLTH

Duluth Holdings

$37.04

3.09 (9.10%)

16:58
12/08/16
12/08
16:58
12/08/16
16:58
Hot Stocks
Breaking Hot Stocks news story on Duluth Holdings »

Duluth Holdings down over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

CFR

Cullen/Frost

$88.38

1.92 (2.22%)

16:55
12/08/16
12/08
16:55
12/08/16
16:55
Syndicate
Breaking Syndicate news story on Cullen/Frost »

Cullen/Frost files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

DTEA

DAVIDsTEA

$9.30

0.15 (1.64%)

16:49
12/08/16
12/08
16:49
12/08/16
16:49
Hot Stocks
DAVIDsTEA appoints Christine Bullen interim president and CEO »

As previously announced,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

ISIL

Intersil

$22.25

0.05 (0.23%)

16:49
12/08/16
12/08
16:49
12/08/16
16:49
Hot Stocks
Intersil stockholders approve merger proposal with Renesas Electronics »

Intersil stockholders…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

DTEA

DAVIDsTEA

$9.30

0.15 (1.64%)

16:47
12/08/16
12/08
16:47
12/08/16
16:47
Earnings
DAVIDsTEA sees FY16 EPS C35c-C40c »

Sees FY16 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

TEL

TE Connectivity

$70.60

0.14 (0.20%)

16:45
12/08/16
12/08
16:45
12/08/16
16:45
Hot Stocks
TE Connectivity raises quarterly dividend to 40c per share from 37c »

TE Connectivity's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLTH

Duluth Holdings

$37.04

3.09 (9.10%)

16:41
12/08/16
12/08
16:41
12/08/16
16:41
Earnings
Duluth Holdings sees FY16 adjusted EBITDA $34M-$38M »

Seees FY16 GAAP EPS in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

16:39
12/08/16
12/08
16:39
12/08/16
16:39
General news
Fed Balance Sheet Level data reported »

Week of 12/7 Fed Balance…

16:39
12/08/16
12/08
16:39
12/08/16
16:39
General news
Money Supply M2 Weekly Change data reported »

Week of 11/28 Money…

ENZ

Enzo Biochem

$7.48

0.2 (2.75%)

, BDX

Becton Dickinson

$163.64

-0.35 (-0.21%)

16:38
12/08/16
12/08
16:38
12/08/16
16:38
Earnings
Enzo Biochem reports Q1 adjusted EPS (3c), one estimate (5c) »

Reports Q1 revenue…

ENZ

Enzo Biochem

$7.48

0.2 (2.75%)

BDX

Becton Dickinson

$163.64

-0.35 (-0.21%)

RHHBY

Roche

$27.08

-0.36 (-1.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

CNS

Cohen & Steers

$37.23

0.48 (1.31%)

16:37
12/08/16
12/08
16:37
12/08/16
16:37
Hot Stocks
Cohen & Steers reports AUM of $56.5B as of November 30 »

Cohen & Steers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AWK

American Water

$73.05

0.39 (0.54%)

16:37
12/08/16
12/08
16:37
12/08/16
16:37
Hot Stocks
NJ American Water to invest $3.6M in Somerset County »

New Jersey American Water…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DEI

Douglas Emmett

$38.61

0.25 (0.65%)

16:34
12/08/16
12/08
16:34
12/08/16
16:34
Hot Stocks
Douglas Emmett increases quarterly cash dividend to 23c per share »

Douglas Emmett has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRIX

IRIDEX

$15.51

0.61 (4.09%)

16:34
12/08/16
12/08
16:34
12/08/16
16:34
Syndicate
IRIDEX announces offering of common stock, no amount given »

IRIDEX expects to use the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BURL

Burlington Stores

$88.47

0.47 (0.53%)

, BLK

BlackRock

$390.33

12.81 (3.39%)

16:33
12/08/16
12/08
16:33
12/08/16
16:33
Hot Stocks
Frank Cooper III resigns from Burlington Stores board of directors »

Burlington Stores (BURL)…

BURL

Burlington Stores

$88.47

0.47 (0.53%)

BLK

BlackRock

$390.33

12.81 (3.39%)

TJX

TJX

$77.98

-0.21 (-0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STBZ

State Bank Financial

$26.90

0.51 (1.93%)

16:33
12/08/16
12/08
16:33
12/08/16
16:33
Hot Stocks
State Bank Financial reports FDIC approval for previously announced transaction »

State Bank Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MED

Medifast

$40.65

0.86 (2.16%)

16:32
12/08/16
12/08
16:32
12/08/16
16:32
Hot Stocks
Medifast raises quarterly dividend 28% to 32c per share »

Medifast announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

BEN

Franklin Resources

$42.02

1.4 (3.45%)

16:32
12/08/16
12/08
16:32
12/08/16
16:32
Hot Stocks
Franklin Resources reports month-end AUM of $714.4B »

Franklin Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APPY

Venaxis

$3.95

-0.28 (-6.62%)

16:32
12/08/16
12/08
16:32
12/08/16
16:32
Hot Stocks
Venaxis changing name and NASDAQ ticker symbol »

Venaxis has changed its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECL

Ecolab

$119.61

0.8 (0.67%)

16:31
12/08/16
12/08
16:31
12/08/16
16:31
Hot Stocks
Ecolab raises quarterly dividend 6% to 37c per share »

The board of directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

16:30
12/08/16
12/08
16:30
12/08/16
16:30
Options
Preliminary option volume of 19.3M today »

Preliminary option volume…

BBRY

BlackBerry

$7.83

0.2 (2.62%)

16:27
12/08/16
12/08
16:27
12/08/16
16:27
Hot Stocks
BlackBerry unveils mobile-security platform for the enterprise of things »

BlackBerry unveiled its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Dec

MCC

Medley Capital

16:25
12/08/16
12/08
16:25
12/08/16
16:25
Earnings
Medley Capital reports Q4 EPS 23c, consensus 22c »

Reports Q4 net asset…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

TAHO

Tahoe Resources

$10.01

-0.03 (-0.30%)

, BLK

BlackRock

$390.33

12.81 (3.39%)

16:24
12/08/16
12/08
16:24
12/08/16
16:24
Hot Stocks
Breaking Hot Stocks news story on Tahoe Resources, BlackRock »

BlackRock cuts passive…

TAHO

Tahoe Resources

$10.01

-0.03 (-0.30%)

BLK

BlackRock

$390.33

12.81 (3.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APTS

Preferred Apartment

$13.80

-0.09 (-0.65%)

16:23
12/08/16
12/08
16:23
12/08/16
16:23
Recommendations
Preferred Apartment analyst commentary  »

Preferred Apartment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.